BYSI Key Statistics, Chart & Performance
The current stock price of BYSI is 1.62 USD. In the past month the price decreased by -12.9%. In the past year, price decreased by -5.26%.
BYSI Technical Analysis
BYSI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BYSI. Both the profitability and financial health of BYSI have multiple concerns.
BYSI Financial Highlights
Over the last trailing twelve months BYSI reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.89% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BYSI Forecast & Estimates
BYSI Ownership
About BYSI
Company Profile
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Company Info
BEYONDSPRING INC
100 Campus Drive, West Side, 4Th Floor, Suite 410
Florham Park NEW JERSEY 10005 US
CEO: Lan Huang
Employees: 40
Phone: 16465284184
BEYONDSPRING INC / BYSI FAQ
What does BYSI do?
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Can you provide the latest stock price for BEYONDSPRING INC?
The current stock price of BYSI is 1.62 USD. The price decreased by -2.99% in the last trading session.
Does BYSI stock pay dividends?
BYSI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BYSI stock?
BYSI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of BYSI stock?
BEYONDSPRING INC (BYSI) operates in the Health Care sector and the Biotechnology industry.
What is BEYONDSPRING INC worth?
BEYONDSPRING INC (BYSI) has a market capitalization of 67.91M USD. This makes BYSI a Micro Cap stock.